Assistant Professor, Surgery, University of Kentucky College of Medicine
Urology
Dr. Paul L. Crispen, MD
|
|
Give Review
Doctor Paul L. Crispen, MD is an expert in the field of Urology. He graduated from Temple University School of Medicine. Paul Crispen is a published doctor. He has 59 publications published. The most current publication "New primary malignancy masquerading as metastatic prostate adenocarcinoma." Paul Crispen accepts Medicare.
Publications
- Stone Size Limits the Use of Hounsfield Units for Prediction of Calcium Oxalate Stone Composition.
- Metabolic bone Disease following urinary diversion in adults.
- Small Renal masses: The effect of illness uncertainty during active surveillance.
- Association of Tumor Size, Location, R.E.N.A.L., PADUA and Centrality Index Score with Perioperative Outcomes and Postoperative Renal Function.
- Enhancing Renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of Renal cell carcinoma.
- Association of clinical and radiographic features with perinephric "sticky" fat.
- NMP-22, Urinary cytology, and cystoscopy: a 1 year comparison study.
- Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons.
- Role of Cytoreductive Nephrectomy in the Era of Targeted Therapy for Renal Cell Carcinoma.
- Hand-Assisted Laparoscopic Partial Nephrectomy Without Formal Collecting System Closure: Perioperative Outcomes in 104 Consecutive Patients.
- Temporal relationship between positive margin rate after laparoscopic radical Prostatectomy and surgical training.
- Treatment of patients with small Renal masses: a survey of the American Urological Association.
- Unclassified Renal cell carcinoma: impact on survival following nephrectomy.
- Penile intraepithelial neoplasia and other premalignant lesions of the penis.
- Multifactorial, site-Specific recurrence model after radical cystectomy for urothelial carcinoma.
- Histological subtype is an independent predictor of outcome for patients with Renal cell carcinoma.
- Outcome of stage T2 or greater renal cell Cancer treated with partial nephrectomy.
- The impact of positive surgical margins on mortality following radical Prostatectomy during the Prostate specific antigen era.
- Radical prostatectomy for prostate Cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life.
- T-cell co-regulatory molecule expression in Renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.
- Radiation therapy after radical Prostatectomy: impact on metastasis and survival.
- Natural history, growth kinetics, and outcomes of untreated clinically localized Renal tumors under active surveillance.
- Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate Cancer tumors and metastases.
- The impact of discordance between biopsy and pathological Gleason scores on survival after radical Prostatectomy.
- Outcomes following partial nephrectomy by tumor size.
- Hormone receptor expression in Renal angiomyolipoma: clinicopathologic correlation.
- Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate Cancer cells via NF-kappaB-dependent pathway.
- Residual prostate Cancer after radiotherapy: a study of radical cystoprostatectomy specimens.
- Predicting growth of solid Renal masses under active surveillance.
- Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell Renal cell carcinoma.
- Predicting disease progression after nephrectomy for localized Renal cell carcinoma: the utility of prognostic models and molecular biomarkers.
- T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
- Pathologic concordance of sporadic synchronous bilateral Renal masses.
- Surgical resection of isolated retroperitoneal lymph node recurrence of Renal cell carcinoma following nephrectomy.
- What is the clinical significance of ipsilateral Renal lesions during nephron-sparing surgery?
- Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic Prostatectomy.
- Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate Cancer.
- Delayed intervention of sporadic Renal masses undergoing active surveillance.
- Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate Cancer cells: implications for chemoprevention.
- Tumor size predicts synchronous metastatic Renal cell carcinoma: implications for surveillance of small Renal masses.
- Enhancing Renal masses with zero net growth during active surveillance.
- Immediate postoperative complications of combined penetrating rectal and Bladder injuries.
- The natural history of observed enhancing Renal masses: meta-analysis and review of the world literature.
- New primary malignancy masquerading as metastatic Prostate adenocarcinoma.
- Methylseleninic acid sensitizes prostate Cancer cells to TRAIL-mediated apoptosis.
- Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy afte...
- Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate Cancer progression.
- The natural history of untreated Renal masses.
- The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral Renal masses.
- Multifocal Renal cell carcinoma: clinicopathologic features and outcomes for tumors
- Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate Cancer cells to TRAIL-mediated apoptosis.
- Functional and oncological outcomes after orthotopic neoBladder reconstruction in women.
- Do percutaneous Renal tumor biopsies at initial presentation affect treatment strategies?
- Editorial comment on: Renal angiomyolipoma: long-term results following selective arterial embolization.
- Cardiopulmonary bypass and Renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?
- Tissue microarrays: one size does not fit all.
- Lymph node dissection at the time of radical nephrectomy for high-risk clear cell Renal cell carcinoma: indications and recommendations for surgical templates.
- Second prize: In-vivo physiological impact of alpha blockade on the porcine ureter with distal Ureteral obstruction.
Schools
Temple University
Procedures Preformed
- AdRenalectomy
- Cystectomy
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- Kidney and Ureter Removal
- View All
Conditions Treated
- Bladder Cancer
- Blood in Urine (Hematuria)
- Chronic Kidney Diseases
- Elevated PSA (Prostate Specific Antigen)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Education
-
Temple University Hospital -
Temple University School of Medicine
Hospital
-
UF Health Shands Hospital
Drug Facts
| NPI NUMBER | 1972793396 | |
| NPPES Provider LastName | CRISPEN | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 326103003 | |
| NPPES Provider State | FL | |
| Specialty Description | Urology | |
| Total Claim Count | 82.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1972793396 |
| Last Name Of The Provider | CRISPEN |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
Dr. Sean P. McLaughlin, MD |
|
Dr. Christopher M. Cassisi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. M L. Moy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Daryl B. Bullen, MD |
|
|
Dr. Thomas F. Stringer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philipp Dahm, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Perinchery Narayan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen L. Deardourff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin K. Canales, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Unyime O. Nseyo, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Cristoforo L. Cama, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adrian B. Clubb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Weil R. Lai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diana C. Kang, MD |
|
|
Dr. Marla J. Wardenburg, MD
This Doctor is OpenDoctor Recommended.
|